Icotrokinra Outshines Deucravacitinib in Head-to-Head Phase 3 Trials for Plaque Psoriasis Treatment Recent Phase 3 trials reveal Icotrokinra's effectiveness over Deucravacitinib for treating moderate-to-severe plaque psoriasis, promising a new oral peptide treatment option.

Icotrokinra Outshines Deucravacitinib in Head-to-Head Phase 3 Trials for Plaque Psoriasis Treatment #USA #Spring_House #Psoriasis #Icotrokinra #Deucravacitinib

Psoriasi una nuova terapia mirata Psoriasi una nuova terapia mirata; il farmaco deucravacitinib per la psoriasi a placche da moderata a grave conferma il profilo di sicurezza.

www.boomerblog.it/2025/08/20/p...
#deucravacitinib, #psoriasi, #trattamento, #terapia

POETYK trial shows clinical benefit of deucravacitinib in psoriatic arthritis Treatment with the TYK2 inhibitor deucravacitinib improved disease activity, joint and skin symptoms, and quality of life among people with active psoriatic arthritis participating in the POETYK…

From #EULAR2025 - Treatment with the TYK2 inhibitor #deucravacitinib improved disease activity, joint and skin symptoms, and quality of life among people with active #PsoriaticArthritis participating in the POETYK PsA-1 trial.

Full story 👉https://buff.ly/dtUKqBk

#MedNews #RheumSky

We're pleased to say that we now have an information sheet available on our website for Deucravacitinib (Sotyku), a medication used to treat moderate to severe psoriasis.

Find out more here ow.ly/pKqO50VfCvg

#Deucravacitinib #Sotyku #Psoriasis

Some amazing new data presented at #AAD2025. A new #Tyk2 hits #PASI100 in 50% of patients, #Deucravacitinib offers new hope for patients with #lupus and astounding safety and efficacy of #Icotrokinra for #psoriasis.

Details at: www.healio.com/news/dermato...
#DermSky #RheumSky